Table 3. Combined past and current treatments for HS by Hurley Stage in patients enrolled in the HS severity questionnaire validation study.
| Hurley Stage | ||||
|---|---|---|---|---|
| I (Mild) (N = 39) |
II (Moderate) (N = 43) |
III (Severe) (N = 35) |
All (N = 117) |
|
| Oral antibiotics | 36 (92.3%) | 42 (97.7%) | 34 (97.1%) | 112 (95.7%) |
| Topical antibiotics | 20 (51.3%) | 30 (69.8%) | 26 (74.3%) | 76 (65.0%) |
| Isotretinoin (oral medication) | 10 (25.6%) | 20 (46.5%) | 23 (65.7%) | 53 (45.3%) |
| Surgery | 10 (25.6%) | 17 (39.5%) | 19 (54.3%) | 46 (39.3%) |
| Oral contraceptive pill | 11 (28.2%) | 13 (30.2%) | 12 (34.3%) | 36 (30.8%) |
| Other oral medication or injection | 10 (25.6%) | 9 (20.9%) | 11 (31.4%) | 30 (25.6%) |
| Adalimumab | 2 (5.1%) | 11 (25.6%) | 10 (28.6%) | 23 (19.7%) |
| Clinical trial of a biologic | 1 (2.6%) | 10 (23.3%) | 4 (11.4%) | 15 (12.8%) |
| Acitretin (oral medication) | 2 (5.1%) | 2 (4.7%) | 6 (17.1%) | 10 (8.5%) |
| Infliximab | 0 (0.0%) | 3 (7.0%) | 4 (11.4%) | 7 (6.0%) |
| Etanercept | 0 (0.0%) | 1 (2.3%) | 0 (0.0%) | 1 (0.9%) |
| Ustekinumab | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |